Neoadjuvant Immunotherapy Shows Promise for Resectable CSCC
-
Neoadjuvant immunotherapy for stage II-IV cutaneous squamous cell carcinoma (CSCC) led to a strong pathological complete response rate, according to results from a stage 2 clinical trial. CSCC hasn't received much attention from pharmaceutical companies, in part because it so often responds well to surgery or local therapy. Still, some patients develop more advanced cancer that requires surgery, often on exposed surfaces like the scalp, face, or neck. That can lead to cosmetic and functional impairment.
-
@prem There are lots of unanswered questions that are really important to how this gets rolled out into clinical practice, but I do think that there's no turning back. The results are so dramatic that it's a very attractive option to patients and providers. We will have to figure out how to learn the best way to use this in practice while it's being used